Seeking Alpha

Gilead maintained a Buy at Deutsche after latest data

  • "IMS recently released week #3 scripts for Sovaldi and our calculations indicate U.S. Q4 sales $53M," says Deutsche's Robyn Karnauskas, maintaining Gilead (GILD -1.1%) at a Buy with $95 price target. Third week new patient starts of 797 compares to 834 in week #2, with the decline likely due to Christmas. "These Sovaldi trends are very early in the launch as we just have three week of scripts."
  • Previous: Karnauskas after week #2.
Comments (1)
  • JAC92651
    , contributor
    Comments (65) | Send Message
     
    I anticipate the ramp up will be fast and the volume will blow away analyst estimates. Long 2015 leaps.
    3 Jan, 02:58 PM Reply Like
DJIA (DIA) S&P 500 (SPY)